Sutro Biopharma STRO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's EPS (diluted)?
- Sutro Biopharma (STRO) reported EPS (diluted) of -$2.94 in Q1 2026.
- How has Sutro Biopharma's EPS (diluted) changed year-over-year?
- Sutro Biopharma's EPS (diluted) increased by 67.6% year-over-year, from -$9.08 to -$2.94.
- What is the long-term trend for Sutro Biopharma's EPS (diluted)?
- Over 3 years (2021 to 2025), Sutro Biopharma's EPS (diluted) has grown at a 137.5% compound annual growth rate (CAGR), from -$2.29 to -$30.67.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.